Clinical Trial Update: Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating conversion therapy with sintilimab plus CAPOX in unresectable locally advanced or limited metastatic stomach/EGJ adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Stomach Adenocarcinoma
• Unresectable Gastric Adenocarcinoma

Drugs mentioned

• CAPOX (capecitabine + oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sichuan University | Conditions: Gastroesophageal Junction Adenocarcinoma, Stomach Adenocarcinoma | Phase 2 | Status: UNKNOWN